Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB-PYRO
- Development stage
- Unknown
- Lead developer
- Adorshea Bioceutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HB-PYRO is an oral iron supplement developed and marketed by Adorshea Bioceutics, primarily indicated for the treatment of iron deficiency anemia. The product is a combination therapy typically containing ferric pyrophosphate, folic acid, and vitamin B12. Ferric pyrophosphate serves as a highly bioavailable source of iron with minimal gastrointestinal side effects, while folic acid and vitamin B12 act as essential cofactors for erythropoiesis and DNA synthesis. Together, these ingredients work to restore hemoglobin levels and replenish iron stores in patients suffering from nutritional deficiencies.
- Brand names
- HB-PYRO
- Other names
- HB-PYRO
Beyond the preview
Go deeper on HB-PYRO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB-PYRO.